Market Research Logo

Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2018

Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia - Pipeline Review, H2 2018, provides an overview of the


Introduction
Global Markets Direct Report Coverage
Spinocerebellar Ataxia (SCA) - Overview
Spinocerebellar Ataxia (SCA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
Bio Blast Pharma Ltd
Biohaven Pharmaceutical Holding Company Ltd
Cadent Therapeutics Inc
Ionis Pharmaceuticals Inc
Lacerta Therapeutics Inc
Shionogi & Co Ltd
Spark Therapeutics Inc
Vybion Inc
WAVE Life Sciences Ltd
Spinocerebellar Ataxia (SCA) - Drug Profiles
2AU-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acetylleucine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit ATXN3 for Spinocerebellar Ataxia Type 3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Ataxin-1 for Spinocerebellar Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Ataxin-7 for Spinocerebellar Ataxia Type 7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASO-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-1883 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Spinocerebellar Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Inhibit ATXN3 for Spinocerebellar Ataxia Type 3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
riluzole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rovatirelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBADSC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trehalose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
troriluzole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Spinocerebellar Ataxia (SCA) - Dormant Projects
Spinocerebellar Ataxia (SCA) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2018: Biohaven reports positive primary results from trial of BHV-0223
May 30, 2018: Kissei Announces Negative Top line Results from the additional phase III Clinical Trial evaluating KPS-0373 (Development Code) for the Treatment of Spinocerebellar Ataxia
Oct 02, 2017: Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia Phase 2/3 Trial
Aug 07, 2017: Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017
Jun 05, 2017: Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger Opportunities
May 30, 2017: Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole
May 15, 2017: Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA
Jan 26, 2017: Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2
Jan 18, 2017: Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)
Dec 22, 2016: Biohaven Enrolls First Patient in Pivotal Trial of BHV-4157 in Patients With Hereditary Spinocerebellar Ataxia
Jul 20, 2016: Biohaven Reports Dosing Of First Subject In Pharmacokinetic And Safety Trial Of BHV-4157
Jul 05, 2016: Biohaven Receives FDA Investigational New Drug Application (IND) Approval for BHV-4157
Jun 01, 2016: Scripps Florida Scientists Create Compound that Erases Disease-Causing RNA Defects
May 27, 2016: Announcement of Additional Clinical Trial of “KPS-0373 for the Treatment of Spinocerebellar Ataxia
May 25, 2016: Portage Announces Orphan Drug Designation Request Granted to Biohaven for BHV-4157
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Spinocerebellar Ataxia (SCA), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Bio Blast Pharma Ltd, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Cadent Therapeutics Inc, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Lacerta Therapeutics Inc, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Spark Therapeutics Inc, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, H2 2018
Spinocerebellar Ataxia (SCA) - Pipeline by WAVE Life Sciences Ltd, H2 2018
Spinocerebellar Ataxia (SCA) - Dormant Projects, H2 2018
List of Figures
Number of Products under Development for Spinocerebellar Ataxia (SCA), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report